Axogen, Inc. (AXGN) 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2026. Axogen, Inc. is a medical technology company focused on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. The company operates as a single segment, deriving substantially all revenue from U.S. sales of products such as Avance, Axoguard, and Avive+.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2026 | Six Months Ended June 30, 2026 |
|---|---|---|
| Revenue | $69.7 million | $131.2 million |
| Gross Profit | $50.7 million | $96.9 million |
| Gross Margin | 72.7% | 73.8% |
| Operating Income (Loss) | $(2.2) million | $(5.0) million |
| Net Income (Loss) | $(1.5) million | $(21.1) million |
| Cash and Cash Equivalents | $94.6 million | $94.6 million (Balance Sheet) |
| Total Investments | $16.8 million | $16.8 million (Balance Sheet) |
| Long-Term Debt | $0 | $0 |
| Current Ratio | 6.6x | 6.6x |
Note: The six-month net loss includes a one-time loss on debt extinguishment of $16.8 million.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 23.1% year-over-year for the quarter and 24.7% for the six-month period, driven by higher unit volumes and price changes across Extremities, Oral Maxillofacial, and Breast markets.
- Debt Elimination: The company fully repaid its $69.7 million Credit Facility in January 2026, eliminating long-term debt and associated interest expenses. This resulted in a $16.8 million non-cash loss on extinguishment of debt recorded in the first half of 2026.
- Equity Financing: In January 2026, the company completed an underwritten public offering of 4.6 million shares, raising net proceeds of $133.3 million. These funds were used to pay off the debt and fund operations.
- Operating Expenses: Total operating expenses increased 30.9% for the quarter, primarily due to higher compensation costs (salaries, commissions) and stock-based compensation driven by anticipated performance target achievements.
- Liquidity: Cash and investments increased significantly from $41.5 million at year-end 2025 to $111.4 million as of June 30, 2026.
Guidance, Outlook, and Risks
- Outlook: Management expects to fund operations for at least the next twelve months using existing cash, investments, and operating cash flows. The strategy focuses on expanding nerve repair indications and deepening adoption in high-potential accounts (Level 1 trauma centers).
- Recent Developments: The FDA approved the Biologics License Application for Avance in December 2025. The company initiated the Nerve-RESTORE clinical study and published Level 1 evidence for Axoguard Nerve Cap.
- Subsequent Event: On July 28, 2026, the company invested $7.0 million in Trace Biosciences to support nerve-specific imaging technology.
- Risks:
- Grant Clawbacks: The company must maintain specific headcount and payroll thresholds through December 31, 2026, to avoid repaying up to $0.95 million in economic development grants.
- Supply Chain: The company relies on third-party vendors for the manufacturing of Axoguard products; loss of these agreements could materially impact the business.
- Macroeconomic Factors: Potential trade disputes and economic instability could affect net revenue.
Investor Verification Checklist
- Debt-Free Status: Confirm the complete removal of the Credit Facility and associated covenants from the balance sheet.
- Grant Milestones: Verify the company's ability to meet the December 31, 2026, job creation milestones to prevent the $0.95 million grant clawback.
- Stock-Based Compensation: Review the impact of the $15.6 million stock-based compensation expense (six months) on future cash burn and dilution.
- Margin Trends: Monitor gross margin compression due to the higher cost of biologic Avance products versus synthetic alternatives.
- Cash Utilization: Track the deployment of the $111.4 million cash balance, specifically the recent $7.0 million investment in Trace Biosciences.